Skip to main content

Table 4 Pharmacokinetic Parameters required for assessment of Montelukast, Gliclazide and Nifedipine Bioavailability

From: Development and validation of LC/MS/MS method for the simultaneous determination of montelukast, gliclazide, and nifedipine and its application to a pharmacokinetic study

Parameters Montelukast Gliclazide Nifedipine
Cmax (ng/mL) 882.39 ± 245.8 2917.2 ± 991.3 353.519 ± 104.5
AUC 0–48 (ng.h/mL) 4493.23 ± 2576.3 45156.15 ± 45988.13 1261.81 ± 155.1
AUC 0-α (ng.h/ml) 4797.49 ± 2808.6 49915.8 ± 51881.3 1423.3 ± 295.5
tmax (median) h 4.25 8.00 4.24
t1/2 (h) 3.86 ± 27 7.24 ± 8.3 2.7 ± 0.36
MRT (h) 7.27 ± 3.7 15.46 ± 11.6 5.88 ± 3.1
Kel (h) 0.282 ± 0.32 0.240 ± 0.17 0.255 ± 0.03